GDRX•benzinga•
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales
Summary
GoodRx reported Q4 revenue of $198.6M, missing expectations. 2025 guidance projects $810M–$840M revenue and adjusted EBITDA of $270M–$286M.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 27, 2025 by benzinga